ArticleOncotarget2017

PPARs as determinants of the estrogen receptor lineage: use of synthetic lethality for the treatment of estrogen receptor-negative breast cancer.

Robert I Glazer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.